Historical azn News Stories
AstraZeneca Stock Jumps on Big Volume Spike
AstraZeneca (AZN) rallied in early December with above-average volume after consecutive U.S. trading gains and a brief U.K. pullback. Elevated volumes on Dec. 8 and 10, plus a modest institutional trim by Russell Investments, highlight renewed investor activity. The move appears driven by broader risk-on sentiment tied to macro data and portfolio rebalancing rather than company-specific headlines.
AstraZeneca (AZN) Hits 52-Week High, Q3 Beat - Now
AstraZeneca surged to a 52-week high after a stronger-than-expected Q3, boosted by revenue and EPS beats and growing momentum for a direct U.S. listing. Institutional buying and modest upward revisions to earnings estimates support near-term upside, while pricing reforms and regional procurement policies remain concrete headwinds.
AZN Soars: $2B U.S. Build & FDA Breast Drug Nod Up
AstraZeneca announced a $2 billion U.S. manufacturing expansion and secured FDA approvals for Datroway (Dato‑DXd) and an expanded Calquence indication. These concrete developments drove AZN to fresh 52‑week highs, underpinned by strengthened production capacity and near‑term commercial catalysts.
AstraZeneca Baxdrostat Win Fuels AZN Nasdaq Surge!
AstraZeneca’s recent Phase III success with baxdrostat, stronger-than-expected Q3 results, and a harmonized listing plan have driven AZN to a one‑year high on the Nasdaq‑100. This article explains the concrete catalysts, operational moves, and near‑term implications for investors.
AstraZeneca $4.5B Virginia Plant Fuels Stock Rally
AstraZeneca's latest week of news — stronger-than-expected Q3 results, a $4.5B Virginia manufacturing commitment, a U.S. government pricing agreement and approval for a direct NYSE listing — pushed AZN higher. Analyst upgrades and unusual options volume added fuel. This article explains the key events, why they matter for investors, and risks to monitor.
AZN: Datroway Gets Second FDA Nod; China Pact $5B
AstraZeneca secured an accelerated FDA approval for Datroway in EGFR‑mutated NSCLC, reaffirming its ADC momentum after earlier breast‑cancer approval. The company also struck a roughly $5 billion research pact with CSPC in China and reported encouraging Phase III data for camizestrant. These concrete developments—plus milestone obligations to Daiichi Sankyo—de‑risk select pipeline assets and provide specific near‑term catalysts for AZN.